Introduction
============

Primary congenital glaucoma (PCG) is a rare but severe form of glaucoma that can lead to blindness from the infantile period. The characteristic findings of PCG include the classic triad of presenting symptoms in the newborn: epiphora, photophobia, and blepharospasm \[[@r1]\]. Elevated intraocular pressure (IOP) causes optic atrophy in the late stage. The incidence of PCG varies from country to country depending on ethnicity. The highest incidence (1 in 1,250) occurs in the Slovakian Romani population with higher rates of consanguinity, while lower incidence (1 in 18,500 to 1 in 30,000) is observed in Western populations \[[@r2],[@r3]\]. The prevalence in the Han Chinese population is approximately 1 in 5,000 to 1 in 25,000 (1 in 10,000 on average) \[[@r4]\]. Several genetic loci have been linked to PCG in family linkage studies, including *GLC3A* (Gene ID: 1545, OMIM \#: [601771](http://omim.org/entry601771); 2p22-p21) \[[@r5]\], *GLC3B* (Gene ID: 2728, OMIM \#: [600975](http://omim.org/entry/600975); 1p36.2-p36.1) \[[@r6]\], *GLC3C* (gene ID: 399565, OMIM \#: [613085](http://omim.org/entry/613085); l4q24.2-q24.3) \[[@r7]\], and *GLC3D* (Gene ID: 4053, OMIM \#: [602091](http://omim.org/entry/602091); 14q24) \[[@r8],[@r9]\]. Two genes have been identified from these loci: *CYP1B1*, coding for cytochrome P450, family 1, subfamily B, polypeptide 1 at *GLC3A* \[[@r10]\], and *LTBP2*, coding for latent transforming growth factor-β-binding protein 2 at *GLC3D* \[[@r8],[@r9]\].

Previous studies showed that mutations in *CYP1B1* are the predominant cause of PCG \[[@r11],[@r12]\]. Populations with a higher mutation frequency of *CYP1B1* in patients with PCG often possess a higher incidence of PCG. For instance, Arab and Romani populations have the highest incidence of PCG, corresponding to the highest mutation frequency of *CYP1B1* in patients with PCG (90% to 100%) \[[@r13]\]. However, in our previous study, only 17.2% of patients with PCG had *CYP1B1* mutations in a Han Chinese population \[[@r14]\], corresponding to the lower incidence of PCG in the Han Chinese population \[[@r4]\]. The low frequencies of *CYP1B1* mutations in patients with PCG from some populations \[[@r14],[@r15]\] indicate that PCG is genetically heterogeneous, and other genes may contribute to the disease.

The *GLC3C* locus spans a region of around 5.77 Mb that contains more than 40 genes, and it has been confirmed and further mapped within a genetic distance of 0.006 cM \[[@r16]\]. *LTBP2* is around 1.3 Mb proximal to the *GLC3C* locus \[[@r8],[@r9]\]. Ocular expression studies have determined the presence of *LTBP2* in the trabecular meshwork and ciliary processes \[[@r17]\]. Recently, *LTBP2* has been verified as essential for the development of ciliary zonule microfibrils \[[@r18]\]. Several studies have shown that *LTBP2* mutations are associated with secondary glaucoma \[[@r19]-[@r22]\]. Null mutations have been found in patients with PCG from Pakistani, Iranian, and Slovakian Romani consanguineous families \[[@r8],[@r9],[@r23]\]. However, the exact role of *LTBP2* in the development of PCG remains unclear. Several studies did not discover any deleterious mutations in *LTBP2* in sporadic PCG North Indian, British, and American cases \[[@r24]-[@r26]\]. Intriguingly, a possible role of *LTBP2* has been suggested in the etiology of primary open angle glaucoma (POAG), primary angle closure glaucoma (PACG), and secondary glaucoma, such as megalocornea, spherophakia, ectopia lentis, Weill-Marchesani syndrome, and pseudoexfoliation syndrome \[[@r19]-[@r22],[@r27],[@r28]\]. In the present study, we screened for mutations in the *LTBP2* gene in a large sample of Chinese patients with PCG, aiming to evaluate the role of *LTBP2* in Chinese patients with PCG.

Methods
=======

Study subjects
--------------

A total of 214 unrelated patients diagnosed with PCG but without mutations in the *CYP1B1* gene were included in this study \[[@r14],[@r29]\]. Briefly, we amplified the coding regions (exons 2 and 3) and the promoter region of *CYP1B1* with PCR and screened for *CYP1B1* mutations with direct sequencing with forward and reverse primers \[[@r14],[@r29]\]. PCR was performed in a 25 µl mixture containing genomic DNA (50 ng), forward and reverse primers (0.5 µmol/l), magnesium chloride (1.5 mmol/l), deoxyribonucleotide triphosphate (dNTP; 0.2 µmol/ml) and Taq polymerase (1 U; Takara Bio Inc, Shiga, Japan), as per the following procedure: initial denaturation at 95 °C for 5 min, 35 cycles of denaturation at 94 °C for 45 s, annealing at a primer-specific temperature for 45 s, extension at 72 °C for 1 min and a final extension at 72 °C for 10 min. We excluded patients who carried *CYP1B1* mutations from the present study. Among these sporadic cases, 152 trios that consisted of one affected proband and two unaffected parents had been used in our previous study of *GLC3C* with the transmission disequilibrium test (TDT) \[[@r16]\]. As the other 62 sporadic cases had only one parent available for genotyping, they were excluded from TDT in our previous study \[[@r16]\]. The diagnosis of PCG was based on the following criteria \[[@r29]\]: 1) Age of diagnosis was less than 3 years old, 2) the cornea was enlarged so that the parameter was bigger than 11 mm or edema with or without Haab striae, 3) IOP was greater than 21 mmHg, and 4) the cup to disk ratio was enlarged or dissymmetric between two eyes. Patients with other ocular or systemic anomalies, such as aniridia, anterior segment dysgenesis, congenital hereditary endothelial dystrophy, neurofibromatosis, and Sturge--Weber syndrome, were excluded.

All patients underwent comprehensive examinations of the anterior segments with slit-lamp and surgical microscope, the structure of anterior chamber angles with gonioscope, and the ocular fundus with a direct ophthalmoscope. IOP was measured with Tono- PEN^®^ (Reichert, Depew, NY) before or during surgery under general anesthesia. Corneal opacity was scored based on the microscope examination, and a higher corneal opacity score indicated a more opaque cornea \[[@r29]\]. The more severe eye was recorded and analyzed when cases were bilateral present.

One hundred ethnically matched unrelated individuals without any ocular or systemic disorders were enrolled as controls. The unaffected parents of the patients with PCG who had sequence changes in *LTBP2* were also included in the study. All the controls and healthy parents were older than 18 years and had normal IOP, open angles on gonioscopy, and normal optic nerves on ocular fundus examination. Peripheral blood samples were collected from patients and controls by venipuncture in EDTA vacutainers and stored in −20 °C until further use.

All study subjects were Han Chinese who live in Mainland China. This study adhered to the ARVO statement on human subjects. This study was approved by the Ethics Committee of the Eye and ENT hospital, Fudan University. Informed written consent was obtained from all study subjects after explanation of the nature and possible consequences of the study, in accordance with the tenets of the Declaration of Helsinki.

Screening for *LTBP2* mutations with Sanger sequencing
------------------------------------------------------

DNA extraction and Sanger sequencing were performed for all 214 patients with PCG using standard methods \[[@r30]\]. The primers were designed to include the intron--exon boundaries of *LTBP2* using the software Primer Premier 5.0 ([Table 1](#t1){ref-type="table"}). Standard PCR conditions were run to amplify all exons and exon--intron boundaries of *LTBP2*. PCR was performed in a 25 µl mixture containing genomic DNA (50 ng), forward and reverse primers (0.5 µmol/l), magnesium chloride (1.5 mmol/l), deoxyribonucleotide triphosphate (dNTP; 0.2 µmol/ml) and Taq polymerase (1 U; Takara Bio Inc, Shiga, Japan), as per the following procedure: initial denaturation at 95 °C for 5 min, 35 cycles of denaturation at 94 °C for 45 s, annealing at a primer-specific temperature for 45 s, extension at 72 °C for 1 min and a final extension at 72 °C for 10 min. All PCR products were analyzed on 2% agarose gel and stained with ethidium-bromide (EB, 10 mg/ml). Then the right size products were purified with spin-columns technology (QIAQuick PCR Purification Kit; Qiagen, Valencia, CA). Using ABI BigDye chemistry (Applied Biosystems Inc., Foster City, CA), Sanger sequencing was performed on the PCR amplicons and was processed through an automated ABI 3730 XL Sequencer (Applied Biosystems). The sequences were scrutinized for variations alongside reference sequences from the University of California, Santa Cruz [Genome Browser website](http://genome.ucsc.edu/index.html) using Sequencher 5.0 software (Gene Codes, Ann Arbor, MI). PCR and Sanger sequencing were subsequently performed on 100 unaffected control samples with identified sequence variants. The unaffected parents of the patients with PCG who had sequence changes in *LTBP2* were also screened for the specific SNPs using Sanger sequencing. The PCR products were first sequenced with forward primers. Further sequencing with reverse primers was performed to confirm the identified variants.

###### PCR Primers used for amplification of *LTBP2* gene.

  **Primer name**   **Forward Primer**              **Reverse Primer**            **Product size (bp)**
  ----------------- ------------------------------- ----------------------------- -----------------------
  **Exon1**         GGGAGAGATGAAAGCAGGCAAGG         AGGTGGAGGCAGCCAGCAGA          350
  **Exon2**         CGTTCAAGTCATCACACTCATTCACA      AAGGGCGAGGGTCCCAGCATT         666
  **Exon3**         TGTGATAGTTTATGACGGAGTTGTTAGGG   GCATTGAGGCAGAGCGGGAG          456
  **Exon3--5**      CTCTGGCTTGGTGTGTCTTTCCC         CAATGCCCCACCCTTTCCTG          1110
  **Exon5--6**      GTGGATGTCGTGGTCAGGGAGGT         GCTAGTCTTGAGAAGGAAATGATGGAG   982
  **Exon7**         TGGGACAGAAAAGGTGGAGGC           GTGACACTGAAAGAAGGGGAGAGA      289
  **Exon8**         CGTCCAGGCTCCTTCCACAG            TCTTGAGATGATGATTAGGCCACTT     559
  **Exon9**         GGACACGCTCTCTGTAAACCTCTGA       TGCCACTCCTCTCCTTTTTTCTTCT     100
  **Exon10--11**    CCCCTGGGCGAGGAGTTGAA            GGCAGTGGAGGAAAAGGAGTG         1027
  **Exon12**        CATCTGTGGAAAGTGCTCTGCTC         TCCCTGACTCTCCTATGGGCTACT      329
  **Exon13--14**    CCTCACATCACTCCTCGCTCCC          GCTGCCATCGGCTGTCTTCC          578
  **Exon15**        AGAGGGGGCATCCCATTTGTATC         AGGAGGAAAAGCCAGTCCCAGAG       354
  **Exon15--16**    GGGGGCATCCCATTTGTATCCT          CCTATTCACACTGACCCAACACATCC    789
  **Exon17**        CATTCACCCAGTACCCGTTCTCAC        GCCCACCGTCTTGGACTTCTCTC       488
  **Exon18**        ACAACAGCCTCCAAGCCACCTCC         GTCCATCCCTCTCCCCAACCAAA       344
  **Exon19**        GCAACAGGGCGGAGGTTACAG           GCAGACCCGAAGGGGATATAGTG       788
  **Exon20**        ATTCTGCGGCACGGTGTTTG            ACTGGGCTGACTTTATGGCTTCC       409
  **Exon21**        ACTGCTTGGACCTTCTGCTTCTTC        GGGGGATGCCCTACTATGACCT        465
  **Exon22**        TTCCCCCTTCTGGGCTTGG             GGCTTCACCCTTCGTTCTTGG         445
  **Exon23**        TCTGATTTATGTGCTAAGTGGTGC        GCTTCTGTTACTGTGTTGAGATGCT     654
  **Exon24**        TCCGTGAGGTGGTTTGAGGC            GGGCAGAGGCAGGTAAGAAGAGT       645
  **Exon25**        ATGGAAGAGGAAGTGGGTGGGG          ATGGGGCAGCGAGTGTGAGAA         710
  **Exon26**        AAGCCAACAGCCAGAGGACAAAC         TGGGGAGTCACGAGTCTCATCAAG      657
  **Exon27**        TCCAGGTTGAATAGCCGACAC           AAACTGAGGCACAGGGAGAGG         422
  **Exon28**        GGCTGACTTGATTTCCCACCCTA         TTTGTCTTTCTGTGCCTGTCTTATTTC   697
  **Exon29**        GCTGGAACAGGAGGTAAGGAGATAA       TGGCAGAATGTGGGGAGTGAG         626
  **Exon30**        AACAAAGAGGACAGAGAGGAGGAGAAG     TCAGAGGGTTGGAAATGAGGGTG       443
  **Exon31**        TCCACCCAACTGGCACTCCTC           CCAAGTCTGGCTTCCGCATCT         783
  **Exon32**        AGAGAAACAGGCGGCAGAACC           AAAATACCAACACTCAGCCATAGGA     897
  **Exon33**        ATGATAGATTGGGCAGAAATAGAGC       GTAGGGAGTAGGTACAGGACTTGGTT    846
  **Exon34**        ATGCCAGGGAAAGCCAAGGA            TGTGGGACGTGGTGGTGTGAG         680
  **Exon35**        TGGGAGTAGGGTGGGGAATGG           AGAAGGTGGGACTGTCGGAGGG        225
  **Exon36**        GCCTGATGTCACGGTGTCTTCC          GCTCCCTACAGCACTCTCCTTTG       281

Statistical analysis
--------------------

Fisher's exact test was used to compare the allele frequencies of the *LTBP2* variants between patients with PCG and controls. A Bonferroni corrected p value of 0.0125 was considered statistically significant.

Results
=======

Clinical features of the patients
---------------------------------

Some clinical features of the patients with PCG in this study are shown in [Figure 1](#f1){ref-type="fig"}. At the preoperative examination, the median IOP was 36 mmHg, with an average corneal diameter of 13.5 mm. The median age of diagnosis was 4.5 months, ranging from birth to 3 years old. The median corneal opacity score was 2, indicating mild corneal haze with visible iris. [Figure 2](#f2){ref-type="fig"} shows the classic clinical features seen in the left eye of a patient with PCG.

![Clinical features of Chinese patients with primary congenital glaucoma.](mv-v22-528-f1){#f1}

![Classic features of Chinese patients with primary congenital glaucoma. **A**: The left eye is obviously bigger than the right eye and mild corneal haze with visible iris. **B**: Intraocular pressure (IOP) was measured with Tono-PEN®. **C**,**D**: The horizontal diameter of the cornea is about 13 mm measured with bisecting compasses. **E**,**F**: The structure of the anterior chamber angle on gonioscopy; absence of angle recess; peripheral iris hypoplasia; tenting of the peripheral iris pigment epithelium. **G**,**H**: The fundi photos show a dissymmetric cup disc ratio.](mv-v22-528-f2){#f2}

Screening for *LTBP2* mutations
-------------------------------

Eight single nucleotide polymorphisms (SNPs) were identified in the coding regions of the *LTBP2* gene in the patients with PCG. All these variants were inherited in a heterozygous manner. Four missense SNPs resulted in the replacement of amino acids ([rs2304707](http://www.ncbi.nlm.nih.gov/snp/?term=rs2304707), [rs116914994](http://www.ncbi.nlm.nih.gov/snp/?term=rs116914994), [rs45468895](http://www.ncbi.nlm.nih.gov/snp/?term=rs45468895), and [rs763035721](http://www.ncbi.nlm.nih.gov/snp/?term=rs763035721), [Table 2](#t2){ref-type="table"}). Two of the SNPs, [rs2304707](http://www.ncbi.nlm.nih.gov/snp/?term=rs2304707) and [rs116914994](http://www.ncbi.nlm.nih.gov/snp/?term=rs116914994), which changed amino acids p.Pro319Gln and p.Arg1429Gln, respectively, were also present in the control subjects. No significant differences in the frequencies of these missense SNPs were found between the patients with PCG and the controls. The other two missense SNPs, [rs45468895](http://www.ncbi.nlm.nih.gov/snp/?term=rs45468895) and [rs763035721](http://www.ncbi.nlm.nih.gov/snp/?term=rs763035721), which changed amino acids p.Ala1204Val and p.Glu1794Lys, respectively, were each found in one patient with PCG. Their unaffected parents also had the same sequence changes, suggesting that these two SNPs were not segregated in these families and, thus, were unlikely to be a disease-causative variant. In addition, four synonymous SNPs were detected in the patients with PCG ([rs61738025](http://www.ncbi.nlm.nih.gov/snp/?term=rs61738025), [rs862031](http://www.ncbi.nlm.nih.gov/snp/?term=rs862031), [rs199805158](http://www.ncbi.nlm.nih.gov/snp/?term=rs199805158), and [rs12586758](http://www.ncbi.nlm.nih.gov/snp/?term=rs12586758)).

###### *LTBP2* polymorphisms identified from patients with primary congenital glaucoma.

  SNP ID        Exon   Sequence change   Amino acid change   Minor allele frequency (%)   P value        
  ------------- ------ ----------------- ------------------- ---------------------------- -------------- ------
  rs2304707     4      c.956C\>A         p\. Pro319Gln       35/370 (9.5)                 7/90 (7.8)     0.62
  rs45468895    24     c.3611C\>T        p\. Ala1204Val      1/428 (0.2)                  0/200 (0.0)    0.49
  rs116914994   29     c.4286G\>A        p\. Arg1429Gln      22/428 (5.1)                 16/200 (8.0)   0.16
  rs763035721   36     c.5380G\>A        p\. Glu1794Lys      1/428 (0.2)                  0/200 (0.0)    0.49

Fisher's exact test was used to compare the allele frequencies of the *LTBP2* variants between PCG patients and controls. A Bonferroni corrected p value of 0.0125 was considered significant.

Discussion
==========

Null mutations in *LTBP2* were initially found to cause PCG in four consanguineous families from Pakistan and in patients of Romani ethnicity \[[@r8]\]. Subsequently, mutations in *LTBP2* were identified in patients with PCG from several other populations, such as Iranian and Slovakian Romani families ([Table 3](#t3){ref-type="table"}) \[[@r9],[@r23]\]. However, several other studies did not discover deleterious mutations in *LTBP2* in sporadic North Indian, British, and American patients with PCG \[[@r24]-[@r26]\]. In the present study, we screened 214 sporadic patients with PCG from the Han Chinese population for mutations in the *LTBP2* gene. We did not find disease-causative mutations in *LTBP2* in the patients with PCG, which is consistent with previous studies \[[@r24]-[@r26]\]. None of the previously reported pathogenic mutations was detected in our study ([Table 3](#t3){ref-type="table"}) \[[@r8],[@r9],[@r23]\]. In addition, the SNP [rs2304707](http://www.ncbi.nlm.nih.gov/snp/?term=rs2304707) identified in this study was also reported as a polymorphism in consanguineous Iranian families with PCG and a Turkish *GLC3C*-linked family with PCG \[[@r9],[@r25]\]. Another SNP [rs862031](http://www.ncbi.nlm.nih.gov/snp/?term=rs862031) has been reported in patients in the United States \[[@r26]\]. None of the other SNPs identified in the present study was reported in patients with PCG in other populations \[[@r8],[@r9],[@r23]\].

###### *LTBP2* mutations/ polymorphisms previously reported in patients with primary congenital glaucoma from other populations.

  **Exon**          **Sequence change**   **Amino acid change**         **SNP ID**            **Population**            **References**
  ----------------- --------------------- ------------------------ -------------------------- ------------------------- ----------------
  **1**             c.331C\>T             p.Gln111X p. Pro319Gln        rs121918356      \*        Pakistan/ Gypsy \*        8 \*
  **1**             c.412delG             p.Ala138ProfsX278        N.A.                       Pakistan/ Gypsy           8, 23
  **4**             c.895C\>T             p.Arg299X                rs121918355                Pakistan, Roma / Gypsy    8
  **4**             C\>A                  p.Pro319Gln                   rs2304707                  American                  26
  **6**             c.1243--1256 del      p.Glu415ArgfsX596             N.A.                       Pakistan/ Gypsy           8
  **6**             c.1287G\>A            p.Leu429Leu              rs61738025                 Iranian                   9, 26
  **Intron 6--7**   N.A.                  g.75070493               rs3742793                       North Indian         24
  **7**             c.1415delC            p.Ser472fsX3             N.A.                       Iranian                   9
  **7**                  G\>T             p.Ser518Ile              N.A.                       American                  26
  **7**             C\>T                  p.Arg548X                N.A.                       American                  26
  **7**             C\>T                  p.Asn560Asn              N.A.                       American                  26
  **14**                 T\>C             p.Thr802Thr                   rs699374              American                       26
  **15**                 C\>T             p.Thr834Thr                   rs862031              American                       26
  **17**                 C\>T             p.Arg905Arg              rs7145480                  American                  26
  **19**            c.2966C\>G            p.Pro989Arg              rs76172717                 Iranian                   9
  **20**            C\>T                  p.Ser1031Ser             rs45473602                 American                  26
  **22**            G\>A                  p.Thr1111Thr             rs61729544                 American                  26
  **26**            C\>T                  p.Arg1284Arg             rs61736977                 American                  26
  **26**            G\>A                  p.Pro1297Pro             rs61738013                 American                  26
  **29**            G\>A                  p.Ala1421Ala             rs61738017                 American                  26
  **33**            c.4808G\>A            p.Arg1603His             rs75200417                 Iranian                   9
  **36**            c.5376delC            p.Tyr1793fsX55           N.A.                       Iranian                   9

N.A., not avaiblable.

In addition to PCG, *LTBP2* has been related to the development of secondary glaucoma, such as megalocornea, spherophakia, ectopia lentis, Weill-Marchesani syndrome, and pseudoexfoliation syndrome \[[@r19],[@r21],[@r22],[@r27]\]. This can be well explained by recent findings in Ltbp2--/-- mice \[[@r18]\]. The mice survived to adulthood but developed lens luxation caused by compromised ciliary zonule formation. The suppression of *LTBP2* expression in cultured human ciliary epithelial cells by siRNA disrupted the formation of the microfibril meshwork by the cells \[[@r18]\]. Supplementation of recombinant *LTBP2* in culture medium not only rescued the microfibril meshwork formation in *LTBP2*-suppressed ciliary epithelial cells but also restored unfragmented and bundled ciliary zonules in Ltbp2 --/-- mouse eyes under organ culture \[[@r18]\]. The LTBP proteins are important components of the extracellular matrix (ECM) that interact with fibrillin microfibrils and have several different roles in microfibril biology. There are four LTBP isoforms in the human genome (LTBP-1, -2, -3, and -4). LTBP-2 is expressed abundantly in elastic tissues and unique in the family as it is the only one that does not bind to latent transforming growth factor-beta (TGF-β) \[[@r31]\]. Several reports indicate that LTBP-2 has a role in the elastic fiber assembly process, especially fibrillin-1 and -2 \[[@r18],[@r32]\]. Whether increased IOP is a primary symptom or a secondary effect of another abnormality caused by *LTBP2* mutations in childhood glaucoma remains controversial.

In summary, we screened for mutations in the *LTBP2* gene in a large sample of Chinese patients with PCG. We did not detect deleterious mutations in *LTBP2*, suggesting that this gene is not a causal gene for PCG in the Han Chinese population.
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